Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Liabilities and Shareholders Equity (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Liabilities and Shareholders Equity for 13 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 22.0% year-over-year to $1.3 billion, compared with a TTM value of $5.7 billion through Dec 2025, up 12.44%, and an annual FY2025 reading of $1.3 billion, down 22.0% over the prior year.
  • Liabilities and Shareholders Equity was $1.3 billion for Q4 2025 at Agios Pharmaceuticals, down from $1.4 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $2.5 billion in Q1 2021 and bottomed at $773.1 million in Q2 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $1.4 billion, with a median of $1.3 billion recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity soared 211.16% in 2021, then tumbled 46.32% in 2022.
  • Year by year, Liabilities and Shareholders Equity stood at $1.4 billion in 2021, then decreased by 13.84% to $1.2 billion in 2022, then decreased by 24.35% to $937.1 million in 2023, then soared by 77.48% to $1.7 billion in 2024, then dropped by 22.0% to $1.3 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for AGIO at $1.3 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.5 billion in Q2 2025.